nach oben

Current Pulmonology Reports

Erschienen in:

01.12.2015 | Bronchiectasis (G Tino, Section Editor)

Inhaled antibiotics for bronchiectasis: are we there yet?

verfasst von: Chris Johnson, Charles S. Haworth

Erschienen in: Current Pulmonology Reports | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Chronic infection in non-CF bronchiectasis is an important risk factor for disease progression, poor quality life, admission to hospital and perhaps reduced life expectancy. The use of long-term oral and inhaled antibiotics has been included in expert consensus-based guidelines but until recently supporting evidence has been weak. The design, duration and size of adequately powered clinical trials remain challenging, and this has been reflected in some of the reported outcomes. In addition, the tolerability of nebulised antibiotics remains an issue. Despite this, it is now possible to include inhaled antibiotics in treatment strategies and be more specific about antibiotic choice and dose. New inhaled antibiotic options continue to be developed. The most difficult challenge to the success of this intensive treatment will be the promotion of patient adherence.

Ringshausen FC et al. Bronchiectasis-associated hospitalizations in Germany, 2005-2011: a population-based study of disease burden and trends. PLoS One. 2013;8(8):e71109.PubMedCentralCrossRefPubMed

Seitz AE et al. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest. 2012;142:432–9.PubMedCentralCrossRefPubMed

Chalmers JD et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576–85.PubMedCentralCrossRefPubMed

Pasteur MC et al. British thoracic society guidelines for non-CF bronchiectasis. Thorax. 2010;65(S1):i1–i58.CrossRefPubMed

Vendrell M et al. Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery. Arch Bronchopneumol. 2008;44:629–40.CrossRef

Cole PJ. Inflammation: a two-edge sword—the model of bronchiectasis. Eur J Respir Dis. 1986;69:6–15.

Purcell P et al. Polymicrobial airway bacterial communities in adult bronchiectasis patients. BMC Microbiol. 2014;14(130):1–11.

Rogers GB et al. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Lancet Respir Med. 2014;2(12):988–96.CrossRefPubMed

Tunney MM et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med. 2013;187(10):1118–26.PubMedCentralCrossRefPubMed

10.

Chalmers JD et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012;186(7):657–65.CrossRefPubMed

11.

Martinez-Garcia MA et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007;132(5):1565–72.CrossRefPubMed

12.

Martinez-Garcia MA et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J. 2014;43(5):1357–67.CrossRefPubMed

13.

Stockley RA et al. Nebulised amoxicillin in chronic purulent bronchiectasis. Clin Ther. 1985;7:593–9.PubMed

14.

Hill SL et al. Short term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high dose orally or by inhalation. Thorax. 1986;41:559–65.PubMedCentralCrossRefPubMed

15.

Hill SL et al. The response of patients with purulent bronchiectasis to antibiotics for four months. Q J Med. 1988;66:163–73.PubMed

16.

Ramsey B et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999;340:23–30.CrossRefPubMed

17.•

Barker AF et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 2000;162:481–5. This prospective study of nebulised tobramycin demonstrated a significant improvement in bacterial load and an improvement in medical condition. However there was a high rate of adverse events associated with the active drug.CrossRefPubMed

18.

Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest. 2005;127:1420–6.CrossRefPubMed

19.•

Murray MP et al. A randomised controlled trial of nebulised gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2011;183:491–9. This single blinded study of long term nebulised gentamicin versus normal saline demonstrated a good microbiological response, improved exercise tolerance, better quality of life and an increased time to first exacerbation.CrossRefPubMed

20.

Serisier DJ, Bowler SD. Randomised controlled trial of nebulised gentamicin in non-cystic fibrosis bronchiectasis…without patient blinding. Am J Respir Crit Care Med. 2012;186(5):461–2. author reply.CrossRefPubMed

21.

Steinfort DP, Steinfort C. Effect of long term nebulised colistin on lung function and quality of life in patients with chronic bronchial sepsis. Intern Med J. 2007;37:495–8.CrossRefPubMed

22.

Dhar R et al. Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa. Thorax. 2010;65:553.CrossRefPubMed

23.•

Haworth CS et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014;189(8):975–82. The first large randomised controlled trial of nebulised colistin in non-CF bronchiectasis. The protocol included the real world scenario of targeted treatment prior to the introduction of nebulised antibiotics. The results were supportive of a positive effect on bacterial load, symptom scores and in those with >80% adherence a clinical meaningful and significant increase in the time to first exacerbation.PubMedCentralCrossRefPubMed

24.

McCoy KS et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178:921–8.PubMedCentralCrossRefPubMed

25.

Retsch-Bogart GZ et al. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest. 2009;135:1223–32.PubMedCentralCrossRefPubMed

26.

Oermann CM et al. An 18 month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol. 2010;45:1121–34.CrossRefPubMed

27.•

Barker AF et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet. 2014;2(9):738–49. Two large randomised controlled trials of nebulised AZLI in non-CF bronchiectasis. There was a high adverse event rate and the studies did not demonstrate a positive clinical benefit. However there are a number of factors relating to study design that are likely to have influenced this outcome.PubMed

28.

Wilson R et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J. 2013;41(5):1107–15.PubMedCentralCrossRefPubMed

29.

Serisier DJ et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo controlled trial. Thorax. 2013;68:812–7.CrossRefPubMed

Titel: Inhaled antibiotics for bronchiectasis: are we there yet?
verfasst von: Chris Johnson
Charles S. Haworth
Publikationsdatum: 01.12.2015
Verlag: Springer US
Erschienen in: Current Pulmonology Reports / Ausgabe 4/2015
Elektronische ISSN: 2199-2428
DOI: https://doi.org/10.1007/s13665-015-0126-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2015

Pharmacological therapies in smoking cessation: an evidence-based update

Waterpipe tobacco-smoking: a new smoking epidemic among the young?

Computed tomography of smoking-related lung disease: review and update

Diagnostic approach to bronchiectasis